

## HORIZON BIOTECHNOLOGY FUND

### Sector experts seeking compelling opportunities across the biotech landscape

The fund seeks to capitalise on biotechnology's rapid growth potential and innovation by focusing on companies we believe can change the practice of medicine. The fund leverages a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments.

### Why invest in the fund




#### Experienced and specialised investment team

The fund benefits from the expertise of dedicated biotechnology specialists with deep scientific backgrounds and a distinguished record of investing in biotechnology stocks.



#### Differentiated fundamental research

Seek to understand the science and the business to identify opportunities and mitigate the clinical and commercial risks inherent in the sector.




#### Disciplined investment process

Balanced across development stage, early commercial and profitable biotechnology companies and augmented by a differentiated Value at Risk Framework designed to mitigate the volatility associated with drug development.

### DRUG LIFE CYCLE – THE SCIENCE AND THE BUSINESS

The team has over 100+ years of combined experience evaluating the **science** and the **business** of bringing drugs to market.



## Portfolio management



**Andy Acker, CFA**

- Portfolio manager since 2018
- Industry since 1996



**Daniel Lyons, Ph.D., CFA**

- Portfolio manager since 2018
- Industry since 2000

## Fund facts

Structure	SICAV
Inception date	10 December 2018
Fund assets	USD 92.04m (as at 31 March 2021)
Benchmark	NASDAQ Biotechnology Total Return Index (NBI)
Sector	Morningstar Equity Biotechnology
Expected tracking error range	400 – 800 bps
Holdings range	50 – 80
Expected annual turnover	~50% due to rebalancing
Position size	Typically 0.5% to 8%
Market cap range	Typically > USD 300m
Base currency	USD

Ranges are reflective of the portfolio managers investment process and style at time of publication. They may not be hard limits and are subject to change without notice. For a list of available share classes, please contact your local sales representative.

## Role in a diversified portfolio

### Portfolio position



**Traditional equity**  
Health care exposure

### Portfolio implementation

- Complement traditional equity strategies

### What this aims to offer investors

- Long-term growth of capital
- Experienced team

FOR MORE INFORMATION, PLEASE VISIT [JANUSHENDERSON.COM/SG](https://www.janushenderson.com/sg)

**Janus Henderson**  
INVESTORS

**Important Information:** The views presented are as of the date published. They are for information purposes only and should not be used or construed as investment, legal or tax advice or as an offer to sell, a solicitation of an offer to buy, or a recommendation to buy, sell or hold any security, investment strategy or market sector. Nothing in this material shall be deemed to be a direct or indirect provision of investment management services specific to any client requirements. Opinions and examples are meant as an illustration of broader themes, are not an indication of trading intent, are subject to change and may not reflect the views of others in the organisation. It is not intended to indicate or imply that any illustration/example mentioned is now or was ever held in any portfolio. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its use. In preparing this document, Janus Henderson Investors has reasonable belief to rely upon the accuracy and completeness of all information available from public sources. **Past performance is no guarantee of future results. Investing involves risk, including the possible loss of principal and fluctuation of value.** Not all products or services are available in all jurisdictions. This material or information contained in it may be restricted by law, may not be reproduced or referred to without express written permission or used in any jurisdiction or circumstance in which its use would be unlawful. Janus Henderson is not responsible for any unlawful distribution of this material to any third parties, in whole or in part. The contents of this material have not been approved or endorsed by any regulatory agency.

Issued in **Singapore** by Janus Henderson Investors (Singapore) Limited (Co. registration no. 199700782N) licensed and regulated by the Monetary Authority of Singapore. This advertisement has not been reviewed by the Monetary Authority of Singapore. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

The Singapore Representative of the Janus Henderson Horizon Funds plc is Janus Henderson Investors (Singapore) Limited and is distributed by authorised distributors. The Prospectus and Product Highlights Sheet of the Fund is available and may be obtained from the Singapore Representative's office and the authorised distributors' offices. Investors should read the prospectus and Product Highlights Sheet before deciding whether to invest in the units of the Fund. Janus Henderson Horizon Fund is an open ended investment company incorporated in Luxembourg as a société d'investissement à capital variable ("SICAV") on 30 May 1985. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost.

The value of an investment and the income from it can fall as well as rise and investors may not get back the amount originally invested. There is no assurance stated objective(s) will be met. There is no assurance that the investment process discussed includes an effort to monitor and manage risk which should not be confused with and does not imply low risk or the ability to control certain risk factors. Various account minimums or other eligibility qualifications apply depending on the investment strategy, vehicle of investor jurisdiction. Investors are advised to consult your intermediary who will give you advice on the product suitability and help you determine how your investment would be consistent with your own investment objectives. The investment decisions are yours and an investment in the Fund may not be suitable for everyone. If in doubt, please contact your intermediary for clarification.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute. © 2021 Morningstar. All rights reserved. Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiary entities. ©Janus Henderson Group plc.